Pull to refresh
Logo
PROTEINA and Twist Bioscience partner to speed AI antibody validation

PROTEINA and Twist Bioscience partner to speed AI antibody validation

New Capabilities

Deal targets the bottleneck between AI-designed antibodies and physical testing

Today: PROTEINA and Twist Bioscience sign validation MOU

Overview

Updated 56 minutes ago

Artificial intelligence can design tens of thousands of antibody candidates in days. Turning those digital sequences into physical molecules for testing still takes months. PROTEINA and Twist Bioscience announced a partnership on August 27, 2026, to collapse that gap.

The deal pairs Twist's large-scale DNA synthesis and antibody expression with PROTEINA's high-speed experimental validation. PROTEINA plans to expand its data production from 40,000 to 1 million antigen-antibody interaction measurements per month by 2028, a 25-fold increase.

Why it matters

AI designs antibodies in hours; physical testing takes months. This partnership targets the bottleneck deciding whether AI drug discovery becomes commercially viable.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

1,000,000/month
PROTEINA's 2028 data production target
Expansion from 40,000 to 1 million antibody interaction measurements per month by 2028.
$40.4M
Twist therapeutics revenue, June 2026 quarter
Up 49% year over year, a rise Twist attributes largely to AI-driven discovery work.
2 weeks
Antibody validation time with PROTEINA's platform
Down from several months, with more than 10,000 antibody sequences screened weekly.
₩3.4B
PROTEINA investment in ABX Biosciences
Made in July 2026, making PROTEINA the largest shareholder in the de novo antibody design firm.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up
Predict 3 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Organizations Involved

Timeline

January 2024 August 2026

5 events Latest: Today
Tap a bar to jump to that date
  1. PROTEINA and Twist Bioscience sign validation MOU

    Today Partnership

    The companies agree to combine Twist's synthesis and expression capacity with PROTEINA's validation platform, targeting the wet-lab bottleneck in AI drug discovery.

  2. PROTEINA invests in ABX Biosciences

    Investment

    PROTEINA puts 3.4 billion won into ABX to become its largest shareholder and commercialize AI-based de novo antibody design.

  3. Samsung Bioepis and PROTEINA sign option agreement

    Partnership

    The two companies agree to co-develop AI-designed antibody candidates by 2027, with Samsung Bioepis holding an option to license results.

  4. Health ministry commits 470 billion won

    Funding

    South Korea's health ministry launches a larger program for AI-designed antibody biopharmaceuticals with PROTEINA and Baek's team.

  5. Science ministry funds AbGPT-3D project

    Funding

    South Korea's science ministry commits 150 billion won to AI antibody design and validation research led by Professor Baek Min-kyung's team and PROTEINA.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2007-2015

DNA synthesis cost collapse (2007-2015)

Next-generation sequencing and silicon-based DNA synthesis drove the cost of reading and writing DNA down by orders of magnitude. Companies like Twist Bioscience built business models around cheap, high-volume synthetic DNA.

Then

Whole-genome sequencing became affordable for research labs.

Now

Low-cost synthesis made large-scale protein and antibody production feasible, enabling the AI-driven pipeline now emerging.

Why this matters now

The Twist-PROTEINA deal depends on the cost curve that made it economical to physically validate thousands of AI-designed antibody candidates.

1980s-1990s

Fabless semiconductor model (1980s-1990s)

Chip design tools advanced faster than chip manufacturing. Companies like Qualcomm and Nvidia designed chips without owning factories, and Taiwan Semiconductor Manufacturing Company built the foundry model to manufacture their designs.

Then

Design-focused firms grew rapidly without capital-intensive fabs.

Now

Specialized foundries became essential infrastructure, splitting design from production permanently.

Why this matters now

AI antibody design now outpaces physical synthesis and testing, creating a market for specialized validation partners like Twist that fill the same role as chip foundries.

Sources

(9)